137 related articles for article (PubMed ID: 23175472)
1. miR-150:targeting MLL leukemia.
Jiang X; Chen J
Oncotarget; 2012 Nov; 3(11):1268-9. PubMed ID: 23175472
[No Abstract] [Full Text] [Related]
2. Mixed lineage rearranged leukaemia: pathogenesis and targeting DOT1L.
Stein EM; Tallman MS
Curr Opin Hematol; 2015 Mar; 22(2):92-6. PubMed ID: 25635757
[TBL] [Abstract][Full Text] [Related]
3. MLL-rearranged mixed phenotype acute leukemia masquerading as B-cell ALL.
Yang W; Tran P; Khan Z; Rezk S; O'Brien S
Leuk Lymphoma; 2017 Jun; 58(6):1498-1501. PubMed ID: 27774846
[No Abstract] [Full Text] [Related]
4. The same site on the integrase-binding domain of lens epithelium-derived growth factor is a therapeutic target for MLL leukemia and HIV.
Murai MJ; Pollock J; He S; Miao H; Purohit T; Yokom A; Hess JL; Muntean AG; Grembecka J; Cierpicki T
Blood; 2014 Dec; 124(25):3730-7. PubMed ID: 25305204
[TBL] [Abstract][Full Text] [Related]
5. MLL-ENL-mediated leukemia initiation at the interface of lymphoid commitment.
Ugale A; Säwén P; Dudenhöffer-Pfeifer M; Wahlestedt M; Norddahl GL; Bryder D
Oncogene; 2017 Jun; 36(22):3207-3212. PubMed ID: 28068328
[TBL] [Abstract][Full Text] [Related]
6. The molecular functions of common and atypical MLL fusion protein complexes.
Takahashi S; Yokoyama A
Biochim Biophys Acta Gene Regul Mech; 2020 Jul; 1863(7):194548. PubMed ID: 32320750
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia.
Liang K; Volk AG; Haug JS; Marshall SA; Woodfin AR; Bartom ET; Gilmore JM; Florens L; Washburn MP; Sullivan KD; Espinosa JM; Cannova J; Zhang J; Smith ER; Crispino JD; Shilatifard A
Cell; 2017 Jan; 168(1-2):59-72.e13. PubMed ID: 28065413
[TBL] [Abstract][Full Text] [Related]
8. [Molecular mechanisms of leukemogenesis in MLL-leukemias].
Yokoyama A
Rinsho Ketsueki; 2011 Aug; 52(8):679-85. PubMed ID: 21897075
[No Abstract] [Full Text] [Related]
9. TanCAR T cells targeting CD19 and CD133 efficiently eliminate MLL leukemic cells.
Li D; Hu Y; Jin Z; Zhai Y; Tan Y; Sun Y; Zhu S; Zhao C; Chen B; Zhu J; Chen Z; Chen S; Li J; Liu H
Leukemia; 2018 Sep; 32(9):2012-2016. PubMed ID: 30046161
[No Abstract] [Full Text] [Related]
10. A systematic description of MLL fusion gene formation.
Wright RL; Vaughan AT
Crit Rev Oncol Hematol; 2014 Sep; 91(3):283-91. PubMed ID: 24787275
[TBL] [Abstract][Full Text] [Related]
11. Mixed-Phenotype Acute Leukemia: Diagnostic Criteria and Pitfalls.
Charles NJ; Boyer DF
Arch Pathol Lab Med; 2017 Nov; 141(11):1462-1468. PubMed ID: 29072953
[TBL] [Abstract][Full Text] [Related]
12. Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia.
Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ
Int J Cancer; 2020 Apr; 146(7):1902-1916. PubMed ID: 31325323
[TBL] [Abstract][Full Text] [Related]
13. Deubiquitinating enzyme inhibitor alleviates cyclin A1-mediated proteasome inhibitor tolerance in mixed-lineage leukemia.
Ge M; Xu Q; Kang T; Li D; Wang R; Chen Z; Xie S; Wang W; Liu H
Cancer Sci; 2021 Jun; 112(6):2287-2298. PubMed ID: 33738896
[TBL] [Abstract][Full Text] [Related]
14. MLL-ENL leukemia burden initiated in femoral diaphysis and preceded by mature B-cell depletion.
Jaracz-Ros A; Lewandowski D; Barroca V; Lavau C; Roméo PH
Haematologica; 2011 Dec; 96(12):1770-8. PubMed ID: 21933859
[TBL] [Abstract][Full Text] [Related]
15. Menin-MLL inhibitors block oncogenic transformation by MLL-fusion proteins in a fusion partner-independent manner.
He S; Malik B; Borkin D; Miao H; Shukla S; Kempinska K; Purohit T; Wang J; Chen L; Parkin B; Malek SN; Danet-Desnoyers G; Muntean AG; Cierpicki T; Grembecka J
Leukemia; 2016 Feb; 30(2):508-13. PubMed ID: 26084867
[No Abstract] [Full Text] [Related]
16. The mixed lineage leukemia (MLL) fusion-associated gene AF4 promotes CD133 transcription.
Mak AB; Nixon AM; Moffat J
Cancer Res; 2012 Apr; 72(8):1929-34. PubMed ID: 22337994
[TBL] [Abstract][Full Text] [Related]
17. Monitoring mixed lineage leukemia expression may help identify patients with mixed lineage leukemia--rearranged acute leukemia who are at high risk of relapse after allogeneic hematopoietic stem cell transplantation.
Liu J; Wang Y; Xu LP; Liu DH; Qin YZ; Chang YJ; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2014 Jul; 20(7):929-36. PubMed ID: 24631740
[TBL] [Abstract][Full Text] [Related]
18. Blinatumomab for paediatric mixed phenotype acute leukaemia.
Bartram J; Balasch-Carulla M; Bhojaraja S; Adams S; Cheng D; Inglott S; Kulkarni N; Mahendrayogam A; O'Connor O; Pavasovic V; Vora A
Br J Haematol; 2021 Oct; 195(2):289-292. PubMed ID: 34254287
[No Abstract] [Full Text] [Related]
19. Aggressive MLL gene rearranged CD7+ CD56+ myeloid / natural killer cell precursor acute leukaemia with extramedullary relapse in the uterus and breast.
Soon G; Lee SY; Wang S
Pathology; 2015 Oct; 47(6):588-91. PubMed ID: 26308138
[No Abstract] [Full Text] [Related]
20. Generation and characterization of bioluminescent xenograft mouse models of MLL-related acute leukemias and in vivo evaluation of luciferase-targeting siRNA nanoparticles.
Fazzina R; Lombardini L; Mezzanotte L; Roda A; Hrelia P; Pession A; Tonelli R
Int J Oncol; 2012 Aug; 41(2):621-8. PubMed ID: 22665135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
